162 related articles for article (PubMed ID: 36124964)
1. Inactivation of RB1, CDKN2A, and TP53 have distinct effects on genomic stability at side-by-side comparison in karyotypically normal cells.
Andersson N; Saba KH; Magnusson L; Nilsson J; Karlsson J; Nord KH; Gisselsson D
Genes Chromosomes Cancer; 2023 Feb; 62(2):93-100. PubMed ID: 36124964
[TBL] [Abstract][Full Text] [Related]
2. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
3. Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1.
Suwala AK; Stichel D; Schrimpf D; Maas SLN; Sill M; Dohmen H; Banan R; Reinhardt A; Sievers P; Hinz F; Blattner-Johnson M; Hartmann C; Schweizer L; Boldt HB; Kristensen BW; Schittenhelm J; Wood MD; Chotard G; Bjergvig R; Das A; Tabori U; Hasselblatt M; Korshunov A; Abdullaev Z; Quezado M; Aldape K; Harter PN; Snuderl M; Hench J; Frank S; Acker T; Brandner S; Winkler F; Wesseling P; Pfister SM; Reuss DE; Wick W; von Deimling A; Jones DTW; Sahm F
Acta Neuropathol; 2021 Jul; 142(1):179-189. PubMed ID: 33876327
[TBL] [Abstract][Full Text] [Related]
4. Inactivating Mutations of RB1 and TP53 Correlate With Sarcomatous Histomorphology and Metastasis/Recurrence in Gastrointestinal Stromal Tumors.
Merten L; Agaimy A; Moskalev EA; Giedl J; Kayser C; Geddert H; Schaefer IM; Cameron S; Werner M; Ströbel P; Hartmann A; Haller F
Am J Clin Pathol; 2016 Dec; 146(6):718-726. PubMed ID: 28028119
[TBL] [Abstract][Full Text] [Related]
5. Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas.
Schaefer IM; Lundberg MZ; Demicco EG; Przybyl J; Matusiak M; Chibon F; Ingram DR; Hornick JL; Wang WL; Bauer S; Baker LH; Lazar AJ; van de Rijn M; Mariño-Enríquez A; Fletcher JA
Cancer; 2021 Aug; 127(15):2666-2673. PubMed ID: 33788262
[TBL] [Abstract][Full Text] [Related]
6. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
[TBL] [Abstract][Full Text] [Related]
7. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.
Nyquist MD; Corella A; Coleman I; De Sarkar N; Kaipainen A; Ha G; Gulati R; Ang L; Chatterjee P; Lucas J; Pritchard C; Risbridger G; Isaacs J; Montgomery B; Morrissey C; Corey E; Nelson PS
Cell Rep; 2020 May; 31(8):107669. PubMed ID: 32460015
[TBL] [Abstract][Full Text] [Related]
8. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.
Markl ID; Jones PA
Cancer Res; 1998 Dec; 58(23):5348-53. PubMed ID: 9850064
[TBL] [Abstract][Full Text] [Related]
9. Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL.
Cobbers JM; Wolter M; Reifenberger J; Ring GU; Jessen F; An HX; Niederacher D; Schmidt EE; Ichimura K; Floeth F; Kirsch L; Borchard F; Louis DN; Collins VP; Reifenberger G
Brain Pathol; 1998 Apr; 8(2):263-76. PubMed ID: 9546285
[TBL] [Abstract][Full Text] [Related]
10. HPV51-associated Leiomyosarcoma: A Novel Class of TP53/RB1-Wildtype Tumor With Predilection for the Female Lower Reproductive Tract.
Williams EA; Montesion M; Lincoln V; Tse JY; Hiemenz MC; Mata DA; Shah BB; Shoroye A; Alexander BM; Werth AJ; Foley-Peres K; Milante RR; Ross JS; Ramkissoon SH; Williams KJ; Adhikari LJ; Zuna RE; LeBoit PE; Lin DI; Elvin JA
Am J Surg Pathol; 2022 Jun; 46(6):729-741. PubMed ID: 35034043
[TBL] [Abstract][Full Text] [Related]
11. Generation and multiomic profiling of a
Zhao H; Cheng Y; Kalra A; Ma K; Zheng Y; Ziman B; Tressler C; Glunde K; Shin EJ; Ngamruengphong S; Khashab M; Singh V; Anders RA; Jit S; Wyhs N; Chen W; Li X; Lin DC; Meltzer SJ
Sci Transl Med; 2022 Nov; 14(673):eabq6146. PubMed ID: 36449602
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9 treatment causes extended TP53-dependent cell cycle arrest in human cells.
Geisinger JM; Stearns T
Nucleic Acids Res; 2020 Sep; 48(16):9067-9081. PubMed ID: 32687165
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive characterization of RB1 mutant and MYCN amplified retinoblastoma cell lines.
Schwermer M; Hiber M; Dreesmann S; Rieb A; Theißen J; Herold T; Schramm A; Temming P; Steenpass L
Exp Cell Res; 2019 Feb; 375(2):92-99. PubMed ID: 30584916
[TBL] [Abstract][Full Text] [Related]
14. Genomic Alterations in Human Papillomavirus-Positive and -Negative Conjunctival Squamous Cell Carcinomas.
Ramberg I; Vieira FG; Toft PB; von Buchwald C; Funding M; Nielsen FC; Heegaard S
Invest Ophthalmol Vis Sci; 2021 Nov; 62(14):11. PubMed ID: 34779821
[TBL] [Abstract][Full Text] [Related]
15. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma.
Yang G; Rajadurai A; Tsao H
J Invest Dermatol; 2005 Dec; 125(6):1242-51. PubMed ID: 16354195
[TBL] [Abstract][Full Text] [Related]
16. Ionizing Radiation Combined with PARP1 Inhibitor Reduces Radioresistance in Prostate Cancer with RB1/TP53 Loss.
Fan Y; Fan H; Quan Z; Wu X
Cancer Invest; 2021 May; 39(5):423-434. PubMed ID: 33683975
[TBL] [Abstract][Full Text] [Related]
17. Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation.
Harms PW; Collie AM; Hovelson DH; Cani AK; Verhaegen ME; Patel RM; Fullen DR; Omata K; Dlugosz AA; Tomlins SA; Billings SD
Mod Pathol; 2016 Mar; 29(3):240-8. PubMed ID: 26743471
[TBL] [Abstract][Full Text] [Related]
18. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
19. Whole chromosome instability resulting from the synergistic effects of pRB and p53 inactivation.
Manning AL; Benes C; Dyson NJ
Oncogene; 2014 May; 33(19):2487-94. PubMed ID: 23792446
[TBL] [Abstract][Full Text] [Related]
20. Expression ratio of CCND1 to CDKN2A mRNA predicts RB1 status of cultured cancer cell lines and clinical tumor samples.
Mizuarai S; Machida T; Kobayashi T; Komatani H; Itadani H; Kotani H
Mol Cancer; 2011 Mar; 10():31. PubMed ID: 21447152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]